Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.
Ourania Tatsis, insider at Vertex Pharmaceuticals

Ourania Tatsis Insider Information

Nia Tatsis, Ph.D., joined Vertex in 2017 and is the company’s Executive Vice President and Chief Regulatory and Quality Officer. In this role, she provides global regulatory leadership and is responsible for managing all regulatory interactions and quality assurance involving the research and development, manufacturing, and commercialization of Vertex’s transformational medicines. In addition to creating and executing the company’s global regulatory strategy, Dr. Tatsis also manages a worldwide team of regulatory professionals.

Prior to joining Vertex, Dr. Tatsis held positions of increasing responsibility at pharmaceutical companies such as Sanofi, Stemnion, Pfizer, and Wyeth. Most recently, she was Vice President, Head of Global Regulatory Affairs, at the Sanofi Genzyme Business Unit focused on Inflammation/Immunology, Rare Disease, Multiple Sclerosis, Ophthalmology, Neurology, and Oncology/Immuno-Oncology.

Dr. Tatsis also worked as an associate staff scientist and research fellow in Immunology and Vaccine Development at the Wistar Institute and completed a post-doctoral research fellowship in Immunology at Thomas Jefferson University. She received her Ph.D. in Cell and Molecular Biology from the University of Vermont and also holds a B.S. in Biology from Temple University.

What is Ourania Tatsis' net worth?

The estimated net worth of Ourania Tatsis is at least $4.03 million as of February 25th, 2020. Dr. Tatsis owns 14,034 shares of Vertex Pharmaceuticals stock worth more than $4,032,249 as of July 3rd. This net worth approximation does not reflect any other investments that Dr. Tatsis may own. Additionally, Dr. Tatsis receives a salary of $1,330,000.00 as EVP at Vertex Pharmaceuticals. Learn More about Ourania Tatsis' net worth.

How old is Ourania Tatsis?

Dr. Tatsis is currently 51 years old. There are 7 older executives and no younger executives at Vertex Pharmaceuticals. The oldest executive at Vertex Pharmaceuticals is Dr. David M. Altshuler M.D., Ph.D., Exec. VP of Global Research & Chief Scientific Officer, who is 57 years old. Learn More on Ourania Tatsis' age.

What is Ourania Tatsis' salary?

As the EVP of Vertex Pharmaceuticals Incorporated, Dr. Tatsis earns $1,330,000.00 per year. There are 3 executives that earn more than Dr. Tatsis. The highest earning executive at Vertex Pharmaceuticals is Dr. Reshma Kewalramani FASN, M.D., CEO, Pres & Director, who commands a salary of $4,270,000.00 per year. Learn More on Ourania Tatsis' salary.

How do I contact Ourania Tatsis?

The corporate mailing address for Dr. Tatsis and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at [email protected] Learn More on Ourania Tatsis' contact information.

Has Ourania Tatsis been buying or selling shares of Vertex Pharmaceuticals?

Ourania Tatsis has not been actively trading shares of Vertex Pharmaceuticals within the last three months. As far as recent transactions, 0 shares of the company's stock in a transaction that occurred on Sunday, July 3rd. Learn More on Ourania Tatsis' trading history.

Who are Vertex Pharmaceuticals' active insiders?

Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), Sangeeta Bhatia (Director), Joshua Boger (Director), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Vertex Pharmaceuticals?

During the last year, Vertex Pharmaceuticals insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $1,956,500.00. During the last year, insiders at the pharmaceutical company sold shares 28 times. They sold a total of 66,555 shares worth more than $18,085,510.14. The most recent insider tranaction occured on June, 24th when CEO Reshma Kewalramani sold 11,689 shares worth more than $3,405,005.70. Insiders at Vertex Pharmaceuticals own 0.4 % of the company. Learn More about insider trades at Vertex Pharmaceuticals.

Information on this page was last updated on 6/24/2022.

Ourania Tatsis Insider Trading History at Vertex Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/17/2022Sell2,833$250.11$708,561.63View SEC Filing Icon  
2/25/2022Sell325$230.95$75,058.75View SEC Filing Icon  
2/18/2022Sell519$231.00$119,889.00View SEC Filing Icon  
2/25/2020Sell1,296$233.17$302,188.3214,034View SEC Filing Icon  
2/18/2020Sell1,279$243.62$311,589.9816,349View SEC Filing Icon  
11/13/2019Sell2,853$205.59$586,548.2710,105View SEC Filing Icon  
10/1/2019Sell188$169.11$31,792.687,696View SEC Filing Icon  
See Full Table

Ourania Tatsis Buying and Selling Activity at Vertex Pharmaceuticals

This chart shows Ourania Tatsis's buying and selling at Vertex Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vertex Pharmaceuticals Company Overview

Vertex Pharmaceuticals logo
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $287.32
Low: $279.42
High: $287.86

50 Day Range

MA: $264.83
Low: $234.96
High: $292.55

2 Week Range

Now: $287.32
Low: $176.36
High: $293.17

Volume

1,459,668 shs

Average Volume

1,677,917 shs

Market Capitalization

$73.48 billion

P/E Ratio

30.24

Dividend Yield

N/A

Beta

0.49
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.